Latest Pharma Insights
Pipeline Watch: Thirteen Approvals And Eighteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 6, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 6, 2026
CapVest Has ‘Ambitious Plans’ For Stada As It Completes Takeover
CapVest has completed its deal to take majority ownership of Stada, promising to inject fresh capital into the company to pursue both organic growth and strategic acquisitions.
HBW Insight - April 6, 2026
CapVest has completed its deal to take majority ownership of Stada, promising to inject fresh capital into the company to pursue both organic growth and strategic acquisitions.
HBW Insight - April 6, 2026
Neurocrine Takes ‘Sensible Way Into Metabolic Disease’ With $2.9bn Soleno Buy
Soleno, which makes a hyperphagia treatment, offers Neurocrine a faster path into metabolic disorders than starting from scratch in treating weight loss disorders.
Scrip - April 6, 2026
Soleno, which makes a hyperphagia treatment, offers Neurocrine a faster path into metabolic disorders than starting from scratch in treating weight loss disorders.
Scrip - April 6, 2026
Xbrane Delays Refiling Ranibizumab Biosimilar With US FDA To Late Spring
Will the fourth time filing of its ranibizumab biosimilar to the FDA be guaranteed for Xbrane, as the firm faces a slight delay due to the contractor’s outstanding corrective actions?
Generics Bulletin - April 6, 2026
Will the fourth time filing of its ranibizumab biosimilar to the FDA be guaranteed for Xbrane, as the firm faces a slight delay due to the contractor’s outstanding corrective actions?
Generics Bulletin - April 6, 2026
Henlius Targets Phesgo With Next-Wave Biosimilar Strategy
China’s regulator has cleared Henlius’ HLX319 for clinical trials, positioning the company among early movers developing a biosimilar to Roche’s subcutaneous Phesgo.
Generics Bulletin - April 6, 2026
China’s regulator has cleared Henlius’ HLX319 for clinical trials, positioning the company among early movers developing a biosimilar to Roche’s subcutaneous Phesgo.
Generics Bulletin - April 6, 2026
Thermo Fisher Accelerates Biosimilars Race With New Platform
Thermo Fisher has launched a new cell line development platform aimed at accelerating biologics timelines and reducing costs, as biosimilar competition intensifies and manufacturers seek faster, scalable and more efficient production solutions.
Generics Bulletin - April 6, 2026
Thermo Fisher has launched a new cell line development platform aimed at accelerating biologics timelines and reducing costs, as biosimilar competition intensifies and manufacturers seek faster, scalable and more efficient production solutions.
Generics Bulletin - April 6, 2026
BioBytes: Evogene Bets On Autonomous Small-Molecule Discovery
Evogene expands its Google Cloud collaboration to layer AI agents onto ChemPass AI, shifting from molecular design toward autonomous, scalable small-molecule drug discovery.
In Vivo - April 6, 2026
Evogene expands its Google Cloud collaboration to layer AI agents onto ChemPass AI, shifting from molecular design toward autonomous, scalable small-molecule drug discovery.
In Vivo - April 6, 2026
HAYA’s Dark Genome Play: Turning ‘Junk DNA’ Into Drug Targets
HAYA Therapeutics is targeting long non-coding RNAs in the “dark genome” to reprogram disease-driving cell states, with a Lilly collaboration and IND-stage cardiac fibrosis program validating the approach.
In Vivo - April 6, 2026
HAYA Therapeutics is targeting long non-coding RNAs in the “dark genome” to reprogram disease-driving cell states, with a Lilly collaboration and IND-stage cardiac fibrosis program validating the approach.
In Vivo - April 6, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.
Scrip - April 6, 2026
In this week's episode: what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.
Scrip - April 6, 2026
US FDA Foods Program Chief Outlines ‘Nimble And Adaptable’ Supplement Industry Regulation
“The industry has grown and changed tremendously in the last 30 plus years, yet the regulatory framework has largely stayed the same,” says FDA Deputy Commissioner Kyle Diamantas. “We'll be setting up the agency to lower costs and enabling regulated industries to increase access to automation.”
HBW Insight - April 6, 2026
“The industry has grown and changed tremendously in the last 30 plus years, yet the regulatory framework has largely stayed the same,” says FDA Deputy Commissioner Kyle Diamantas. “We'll be setting up the agency to lower costs and enabling regulated industries to increase access to automation.”
HBW Insight - April 6, 2026
‘Dietary Substance For Use By Man To Supplement The Diet’: Open Or Closed Door For Innovation?
The phrase “a dietary substance for use by man to supplement the diet by increasing the total dietary intake,” known as “Clause E” [21 USC 321 (ff)(E)], is prompting what will comparatively be countless words in comments to FDA about the future of NDIs for the US.
HBW Insight - April 6, 2026
The phrase “a dietary substance for use by man to supplement the diet by increasing the total dietary intake,” known as “Clause E” [21 USC 321 (ff)(E)], is prompting what will comparatively be countless words in comments to FDA about the future of NDIs for the US.
HBW Insight - April 6, 2026
Pipeline Watch: Thirteen Approvals And Eighteen Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 6, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 6, 2026
Neurocrine Takes ‘Sensible Way Into Metabolic Disease’ With $2.9bn Soleno Buy
Soleno, which makes a hyperphagia treatment, offers Neurocrine a faster path into metabolic disorders than starting from scratch in treating weight loss disorders.
Scrip - April 6, 2026
Soleno, which makes a hyperphagia treatment, offers Neurocrine a faster path into metabolic disorders than starting from scratch in treating weight loss disorders.
Scrip - April 6, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.
Scrip - April 6, 2026
In this week's episode: what Lilly’s Centessa buy brings; Apellis brings capabilities to Biogen: Chinese firms’ rapid obesity progress; orals take center stage in obesity; and a dip in the global pharma pipeline.
Scrip - April 6, 2026
LSI Panel Says Women’s Health Breaks Out Of ‘Bikini Box’ As New Business Models Catch Investors’ Eye
At the LSI USA conference in Dana Point, CA, a panel of women’s health leaders from Hologic, Teal Health, Bloomlife, Pretika Medtech as well as investors discussed the need to expand the definition of women’s health to attract investors, plus new monetization models and their outlook.
Medtech Insight - April 3, 2026
At the LSI USA conference in Dana Point, CA, a panel of women’s health leaders from Hologic, Teal Health, Bloomlife, Pretika Medtech as well as investors discussed the need to expand the definition of women’s health to attract investors, plus new monetization models and their outlook.
Medtech Insight - April 3, 2026
FDA Releases Trove Of Data On Use of Real-World Evidence In Device Clearances
A new report outlines use of real-world evidence in 73 post-2021 device submissions, reflecting the agency’s growing comfort with data drawn from medical records, registries and even data generated by the devices themselves.
Medtech Insight - April 3, 2026
A new report outlines use of real-world evidence in 73 post-2021 device submissions, reflecting the agency’s growing comfort with data drawn from medical records, registries and even data generated by the devices themselves.
Medtech Insight - April 3, 2026
No Evidence Of Benefit: Two Trials Prompt Calls to End Routine Use Of J&J’s Impella Heart Pump
Two randomized trials presented at a recent American College of Cardiology annual meeting failed to show benefit for J&J's Impella pumps – and one found higher mortality in the device arm.
Medtech Insight - April 3, 2026
Two randomized trials presented at a recent American College of Cardiology annual meeting failed to show benefit for J&J's Impella pumps – and one found higher mortality in the device arm.
Medtech Insight - April 3, 2026
Washington Sleep Doctor Gets Year In Prison For Distributing Recalled Philips CPAP, BiPAP Devices
Eric Haegar pleaded guilty to medical device adulteration. He bought recalled Philips Respironics devices online and pried out the hazardous foam inside before passing the products along to Medicaid patients. He then billed Medicaid as though the devices were new.
Medtech Insight - April 3, 2026
Eric Haegar pleaded guilty to medical device adulteration. He bought recalled Philips Respironics devices online and pried out the hazardous foam inside before passing the products along to Medicaid patients. He then billed Medicaid as though the devices were new.
Medtech Insight - April 3, 2026
CapVest Has ‘Ambitious Plans’ For Stada As It Completes Takeover
CapVest has completed its deal to take majority ownership of Stada, promising to inject fresh capital into the company to pursue both organic growth and strategic acquisitions.
HBW Insight - April 6, 2026
CapVest has completed its deal to take majority ownership of Stada, promising to inject fresh capital into the company to pursue both organic growth and strategic acquisitions.
HBW Insight - April 6, 2026
US FDA Foods Program Chief Outlines ‘Nimble And Adaptable’ Supplement Industry Regulation
“The industry has grown and changed tremendously in the last 30 plus years, yet the regulatory framework has largely stayed the same,” says FDA Deputy Commissioner Kyle Diamantas. “We'll be setting up the agency to lower costs and enabling regulated industries to increase access to automation.”
HBW Insight - April 6, 2026
“The industry has grown and changed tremendously in the last 30 plus years, yet the regulatory framework has largely stayed the same,” says FDA Deputy Commissioner Kyle Diamantas. “We'll be setting up the agency to lower costs and enabling regulated industries to increase access to automation.”
HBW Insight - April 6, 2026
‘Dietary Substance For Use By Man To Supplement The Diet’: Open Or Closed Door For Innovation?
The phrase “a dietary substance for use by man to supplement the diet by increasing the total dietary intake,” known as “Clause E” [21 USC 321 (ff)(E)], is prompting what will comparatively be countless words in comments to FDA about the future of NDIs for the US.
HBW Insight - April 6, 2026
The phrase “a dietary substance for use by man to supplement the diet by increasing the total dietary intake,” known as “Clause E” [21 USC 321 (ff)(E)], is prompting what will comparatively be countless words in comments to FDA about the future of NDIs for the US.
HBW Insight - April 6, 2026
Xbrane Delays Refiling Ranibizumab Biosimilar With US FDA To Late Spring
Will the fourth time filing of its ranibizumab biosimilar to the FDA be guaranteed for Xbrane, as the firm faces a slight delay due to the contractor’s outstanding corrective actions?
Generics Bulletin - April 6, 2026
Will the fourth time filing of its ranibizumab biosimilar to the FDA be guaranteed for Xbrane, as the firm faces a slight delay due to the contractor’s outstanding corrective actions?
Generics Bulletin - April 6, 2026
Henlius Targets Phesgo With Next-Wave Biosimilar Strategy
China’s regulator has cleared Henlius’ HLX319 for clinical trials, positioning the company among early movers developing a biosimilar to Roche’s subcutaneous Phesgo.
Generics Bulletin - April 6, 2026
China’s regulator has cleared Henlius’ HLX319 for clinical trials, positioning the company among early movers developing a biosimilar to Roche’s subcutaneous Phesgo.
Generics Bulletin - April 6, 2026
Thermo Fisher Accelerates Biosimilars Race With New Platform
Thermo Fisher has launched a new cell line development platform aimed at accelerating biologics timelines and reducing costs, as biosimilar competition intensifies and manufacturers seek faster, scalable and more efficient production solutions.
Generics Bulletin - April 6, 2026
Thermo Fisher has launched a new cell line development platform aimed at accelerating biologics timelines and reducing costs, as biosimilar competition intensifies and manufacturers seek faster, scalable and more efficient production solutions.
Generics Bulletin - April 6, 2026
BioBytes: Evogene Bets On Autonomous Small-Molecule Discovery
Evogene expands its Google Cloud collaboration to layer AI agents onto ChemPass AI, shifting from molecular design toward autonomous, scalable small-molecule drug discovery.
In Vivo - April 6, 2026
Evogene expands its Google Cloud collaboration to layer AI agents onto ChemPass AI, shifting from molecular design toward autonomous, scalable small-molecule drug discovery.
In Vivo - April 6, 2026
HAYA’s Dark Genome Play: Turning ‘Junk DNA’ Into Drug Targets
HAYA Therapeutics is targeting long non-coding RNAs in the “dark genome” to reprogram disease-driving cell states, with a Lilly collaboration and IND-stage cardiac fibrosis program validating the approach.
In Vivo - April 6, 2026
HAYA Therapeutics is targeting long non-coding RNAs in the “dark genome” to reprogram disease-driving cell states, with a Lilly collaboration and IND-stage cardiac fibrosis program validating the approach.
In Vivo - April 6, 2026